Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

248.82

-4.22 (1.67%)

as of Jul 20, 2026, 8:00:00 pm Market Open.

697 watching

Investor Insights

Jul 20, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has faced challenges in its cardio business, but experts are generally optimistic about its future, especially following a recent earnings report. The company is transitioning into a pharmaceutical pure-play after spinning off its orthopedics division, which has helped bolster its position in higher-margin sectors such as medical devices and pharmaceuticals. Many analysts believe that despite past legal issues related to talcum powder lawsuits, these concerns have diminished and are unlikely to significantly impact the stock's future performance. With a strong pipeline of drugs, particularly in oncology, JNJ's stock is seen as a promising investment, especially for dividend growth. Overall, the sentiment indicates that buyers may want to capitalize on potential weakness in the stock.

Consensus

Buy

Valuation

Fair Value

Similar

P&GA,PG

WAIT

Sold off when it broke a technical signal in the early spring. Starting to look interesting at this price. Has a lot of free cash flow. It's only 50% pharmaceutical with the rest being consumer products. All the big pharmas are under pressure because of some hearings in the next few weeks.

BUY

This has not been a great environment in the last few years for drug stocks, but J&J has been an exception. A diversified medical company with all kinds of businesses. Has been the best performing drug stock and thinks it will continue to be.

TRADE

The only drug company they own and it is for the medical devices and for the consumer products rather than the pharmaceuticals.

TRADE

Has the best fundamentals of all the drug stocks. Drug sector has come under a number of significant pressures.

BUY

A great company. Feels the US$ will drop so there is a modest exchange risk.

BUY

May be considered boring, but the stability in terms of earnings is going to work well as a theme in the sector.

BUY

Widely diversified product line and not like normal pharmaceutical companies.

TOP PICK

A great business. Low valuation.

TOP PICK

Good ballast for portfolios. Cheap valuation.

TOP PICK

2% yield. Didn't do much over the last year but is starting to recover with different products. On a valuation basis compared to their peers, they are at a much deeper discount. A safe investment.

TOP PICK

Pays a little over 2% dividend. A multitude of products. Terrific track record of making money. A safe place to be in uncertain times.

TOP PICK

With the feds tightening and profit growths slowing, the market is going ahead for higher quality stocks. A well-run company and is not expensive.

BUY

Likes the longer-term outlook for pharmaceuticals. Historically, they have performed relatively well when interest rates are going up.

BUY

Health-care sector is the best sector to be in. Can't think of anything better than this stock. Wide range of products.

DON'T BUY

Big pharmas have a problem of being too big and gets more leverage through Boston Scientific.

Showing 571 to 585 of 628 entries

Most Recent Experts

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

David Driscoll

Liberty International Investment Management Inc

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)